• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Drug Eluting Stents for Very Long Lesions: Go Long, But Know the Risks.

作者信息

Beale Charles E, Dawn Abbott J

机构信息

Division of Cardiology, Rhode Island Hospital, Brown Medical School, Providence, Rhode Island.

出版信息

Catheter Cardiovasc Interv. 2017 May;89(6):992-993. doi: 10.1002/ccd.27073.

DOI:10.1002/ccd.27073
PMID:28488403
Abstract

Long coronary artery lesions are increasingly treated with new technologies including current generation drug eluting stents (DES) despite a lack of robust data on outcomes. In the current study, patients receiving Xience V DES for very long lesions (>35 mm) compared to lesions 25-35 mm had similar outcomes. Future research should address late outcomes, stent thrombosis rates, as well as investigation of lesions greater than 60 mm.

摘要

相似文献

1
Drug Eluting Stents for Very Long Lesions: Go Long, But Know the Risks.
Catheter Cardiovasc Interv. 2017 May;89(6):992-993. doi: 10.1002/ccd.27073.
2
Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) Randomized Trials.经皮冠状动脉介入治疗后病变长度和血管大小对临床结局的影响：来自 SPIRIT（依维莫司洗脱冠状动脉支架系统 XIENCE V 的临床评估）和 COMPARE（真实世界中第二代依维莫司洗脱和紫杉醇洗脱支架）随机试验的汇总分析。
JACC Cardiovasc Interv. 2011 Nov;4(11):1209-15. doi: 10.1016/j.jcin.2011.07.016.
3
Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: clinical and angiographic results from the SPIRIT III randomized trial.基于性别的 XIENCE V 依维莫司洗脱冠状动脉支架系统评估：来自 SPIRIT III 随机试验的临床和血管造影结果。
Catheter Cardiovasc Interv. 2009 Nov 1;74(5):719-27. doi: 10.1002/ccd.22067.
4
Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.经皮冠状动脉介入治疗的最新进展：药物洗脱支架的演变，聚焦于XIENCE V药物洗脱支架。
Coron Artery Dis. 2010 Jan;21(1):46-56. doi: 10.1097/MCA.0b013e328333f550.
5
3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions).3 年临床随访结果：新一代西罗莫司洗脱冠状动脉支架系统（XIENCE V）治疗初发冠状动脉病变的 SPIRIT II 临床试验（新一代西罗莫司洗脱冠状动脉支架系统治疗初发冠状动脉病变的临床评估）。
JACC Cardiovasc Interv. 2009 Dec;2(12):1190-8. doi: 10.1016/j.jcin.2009.10.002.
6
5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).SPIRIT III 试验的 5 年随机对照研究结果：依维莫司洗脱 XIENCE V 支架与紫杉醇洗脱 Taxus 支架的比较——治疗初发的 native 冠状动脉病变患者的 XIENCE V 依维莫司洗脱冠状动脉支架系统的临床评估。
JACC Cardiovasc Interv. 2013 Dec;6(12):1263-6. doi: 10.1016/j.jcin.2013.07.009. Epub 2013 Nov 13.
7
Stent coverage and neointimal proliferation in bare metal stents postdilated with a Paclitaxel-eluting balloon versus everolimus-eluting stents: prospective randomized study using optical coherence tomography at 6-month follow-up.紫杉醇洗脱球囊后扩张与依维莫司洗脱支架治疗裸金属支架：使用光学相干断层成像术在 6 个月随访时的前瞻性随机研究。
Circ Cardiovasc Interv. 2014 Dec;7(6):760-7. doi: 10.1161/CIRCINTERVENTIONS.113.001146. Epub 2014 Nov 4.
8
A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).XIENCE V 依维莫司洗脱冠状动脉支架系统治疗多支冠状动脉疾病患者的临床和血管造影研究：EXECUTIVE 试验（EXecutive RCT：评估 XIENCE V 在多支血管疾病中的应用）。
JACC Cardiovasc Interv. 2013 Oct;6(10):1012-22. doi: 10.1016/j.jcin.2013.05.016. Epub 2013 Sep 18.
9
Paclitaxel-coated balloon for the treatment of drug-eluting stent restenosis: subanalysis results from the Valentines I trial.用于治疗药物洗脱支架再狭窄的紫杉醇涂层球囊：情人节 I 试验的亚组分析结果
Cardiovasc Revasc Med. 2014 Jan;15(1):23-8. doi: 10.1016/j.carrev.2013.08.011.
10
A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods.一项前瞻性随机研究，使用光学相干断层扫描评估冠状动脉依维莫司洗脱支架与紫杉醇洗脱球囊后扩张的金属裸支架在植入后 6 个月时的内皮覆盖和新生内膜增殖情况（OCTOPUS 试验）：原理、设计和方法。
EuroIntervention. 2011 May;7 Suppl K:K93-9. doi: 10.4244/EIJV7SKA16.

引用本文的文献

1
Outcomes of the Novel Supreme Drug-Eluting Stent in Complex Coronary Lesions: A PIONEER III Substudy.新型至尊药物洗脱支架在复杂冠状动脉病变中的应用结果：一项先锋III亚研究
J Soc Cardiovasc Angiogr Interv. 2022 Jan 30;1(1):100004. doi: 10.1016/j.jscai.2021.100004. eCollection 2022 Jan-Feb.
2
Evaluation of Mechanical Performances of Stents with 38 mm Length in Long Lesion.评价 38mm 长度支架在长病变中的机械性能。
Biomed Res Int. 2020 Feb 27;2020:2594161. doi: 10.1155/2020/2594161. eCollection 2020.